Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 3
1985 5
1986 6
1987 30
1988 14
1989 13
1990 36
1991 20
1992 60
1993 40
1994 26
1995 22
1996 55
1997 67
1998 87
1999 92
2000 127
2001 167
2002 148
2003 157
2004 184
2005 175
2006 177
2007 188
2008 161
2009 142
2010 161
2011 139
2012 170
2013 192
2014 153
2015 178
2016 178
2017 161
2018 176
2019 175
2020 154
2021 167
2022 118
Text availability
Article attribute
Article type
Publication date

Search Results

3,972 results
Results by year
Filters applied: . Clear all
Page 1
Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial.
Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR Jr, das Dores Cruz F, Gonçalves Brandão SM, Rigaud VOC, Higuchi-Dos-Santos MH, Hajjar LA, Kalil Filho R, Hoff PM, Sahade M, Ferrari MSM, de Paula Costa RL, Mano MS, Bittencourt Viana Cruz CB, Abduch MC, Lofrano Alves MS, Guimaraes GV, Issa VS, Bittencourt MS, Bocchi EA. Avila MS, et al. J Am Coll Cardiol. 2018 May 22;71(20):2281-2290. doi: 10.1016/j.jacc.2018.02.049. Epub 2018 Mar 11. J Am Coll Cardiol. 2018. PMID: 29540327 Free article. Clinical Trial.
A significant difference existed between groups in troponin I levels over time, with lower levels in the carvedilol group (p = 0.003). Additionally, a lower incidence of diastolic dysfunction was noted in the carvedilol group (p = 0.039). ...(Carvedilol Effec …
A significant difference existed between groups in troponin I levels over time, with lower levels in the carvedilol group (p = 0.003) …
Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices.
Zacharias AP, Jeyaraj R, Hobolth L, Bendtsen F, Gluud LL, Morgan MY. Zacharias AP, et al. Cochrane Database Syst Rev. 2018 Oct 29;10(10):CD011510. doi: 10.1002/14651858.CD011510.pub2. Cochrane Database Syst Rev. 2018. PMID: 30372514 Free PMC article. Review.
OBJECTIVES: To assess the beneficial and harmful effects of carvedilol compared with traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices. ...AUTHORS' CONCLUSIONS: We found no clear beneficial or harmful effects of carvedilol
OBJECTIVES: To assess the beneficial and harmful effects of carvedilol compared with traditional, non-selective beta-blockers for adu …
Carvedilol attenuates carbon tetrachloride-induced liver fibrosis and hepatic sinusoidal capillarization in mice.
Wu Y, Li Z, Xiu AY, Meng DX, Wang SN, Zhang CQ. Wu Y, et al. Drug Des Devel Ther. 2019 Aug 1;13:2667-2676. doi: 10.2147/DDDT.S210797. eCollection 2019. Drug Des Devel Ther. 2019. PMID: 31534314 Free PMC article.
The mice were divided into five experimental groups: the normal group, the oil group, the CCl(4) group, the CCl(4)+carvedilol (5 mg/kg/d) group, and the CCl(4)+carvedilol (10 mg/kg/d) group. ...RESULTS: Liver fibrosis in CCl(4)-treated mice was attenuated by reduced …
The mice were divided into five experimental groups: the normal group, the oil group, the CCl(4) group, the CCl(4)+carvedilol (5 mg/k …
Pharmacokinetic variability of beta-adrenergic blocking agents used in cardiology.
Ågesen FN, Weeke PE, Tfelt-Hansen P, Tfelt-Hansen J; for ESCAPE‐NET. Ågesen FN, et al. Pharmacol Res Perspect. 2019 Jul 12;7(4):e00496. doi: 10.1002/prp2.496. eCollection 2019 Aug. Pharmacol Res Perspect. 2019. PMID: 31338197 Free PMC article. Review.
The C(max) and AUC were reported a total of 672 times in 192 papers. Based on AUC, metoprolol, propranolol, carvedilol, and nebivolol showed high pharmacokinetic variability (highest first), whereas bisoprolol, atenolol, sotalol, labetalol, nadolol, and pindolol showed low …
The C(max) and AUC were reported a total of 672 times in 192 papers. Based on AUC, metoprolol, propranolol, carvedilol, and nebivolol …
Carvedilol attenuates liver fibrosis by suppressing autophagy and promoting apoptosis in hepatic stellate cells.
Meng D, Li Z, Wang G, Ling L, Wu Y, Zhang C. Meng D, et al. Biomed Pharmacother. 2018 Dec;108:1617-1627. doi: 10.1016/j.biopha.2018.10.005. Epub 2018 Oct 10. Biomed Pharmacother. 2018. PMID: 30372864 Free article.
Carvedilol has been identified as a promising agent for the treatment of liver fibrosis. ...Moreover, carvedilol treatment led to the accumulation of yellow dots only in GFP-RFP-LC3-LX-2 cells, similar to the results following CQ treatment, indicating that carved
Carvedilol has been identified as a promising agent for the treatment of liver fibrosis. ...Moreover, carvedilol treatment led
β-arrestin 2 as an activator of cGAS-STING signaling and target of viral immune evasion.
Zhang Y, Li M, Li L, Qian G, Wang Y, Chen Z, Liu J, Fang C, Huang F, Guo D, Zou Q, Chu Y, Yan D. Zhang Y, et al. Nat Commun. 2020 Nov 26;11(1):6000. doi: 10.1038/s41467-020-19849-9. Nat Commun. 2020. PMID: 33243993 Free PMC article.
In vitro, viral infection induces the degradation of beta-arrestin 2 to facilitate immune evasion, while a beta-blocker, carvedilol, rescues beta-arrestin 2 expression to maintain the antiviral immune response. Our results thus identify a viral immune-evasion pathway via t …
In vitro, viral infection induces the degradation of beta-arrestin 2 to facilitate immune evasion, while a beta-blocker, carvedilol, …
Conversion of Propranolol to Carvedilol Improves Renal Perfusion and Outcome in Patients With Cirrhosis and Ascites.
Kalambokis GN, Christaki M, Tsiakas I, Despotis G, Fillipas-Ntekouan S, Fotopoulos A, Tsiouris S, Xourgia X, Lakkas L, Pappas K, Michalis LK, Sergianiti F, Baltayiannis G, Christodoulou D, Koustousi C, Aggelis N, Milionis H. Kalambokis GN, et al. J Clin Gastroenterol. 2021 Sep 1;55(8):721-729. doi: 10.1097/MCG.0000000000001431. J Clin Gastroenterol. 2021. PMID: 32991355 Clinical Trial.
BACKGROUND: In recent years, concerns have been raised on the potential adverse effects of nonselective beta-blockers, and particularly carvedilol, on renal perfusion and survival in decompensated cirrhosis with ascites. ...These patients were randomized in a 2:1 ratio to …
BACKGROUND: In recent years, concerns have been raised on the potential adverse effects of nonselective beta-blockers, and particularly c
Outcomes of beta blocker use in cocaine-associated chest pain: a meta-analysis.
Pham D, Addison D, Kayani W, Misra A, Jneid H, Resar J, Lakkis N, Alam M. Pham D, et al. Emerg Med J. 2018 Sep;35(9):559-563. doi: 10.1136/emermed-2017-207065. Epub 2018 Jun 19. Emerg Med J. 2018. PMID: 29921621 Free PMC article. Review.
METHODS: We searched the MEDLINE and EMBASE databases through September 2016 using the keywords 'beta blocker', 'cocaine' and commonly used beta-blockers ('atenolol', 'bisoprolol', 'carvedilol', 'esmolol', 'metoprolol' and 'propranolol') to identify studies evaluating beta …
METHODS: We searched the MEDLINE and EMBASE databases through September 2016 using the keywords 'beta blocker', 'cocaine' and commonly used …
Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer.
Guglin M, Krischer J, Tamura R, Fink A, Bello-Matricaria L, McCaskill-Stevens W, Munster PN. Guglin M, et al. J Am Coll Cardiol. 2019 Jun 11;73(22):2859-2868. doi: 10.1016/j.jacc.2019.03.495. J Am Coll Cardiol. 2019. PMID: 31171092 Free PMC article. Clinical Trial.
For the entire cohort, cardiotoxicity was comparable in the 3 arms and occurred in 32% of patients on placebo, 29% on carvedilol, and 30% on lisinopril. For patients receiving anthracyclines, the event rates were higher in the placebo group (47%) than in the lisinopril (37 …
For the entire cohort, cardiotoxicity was comparable in the 3 arms and occurred in 32% of patients on placebo, 29% on carvedilol, and …
Effect of carvedilol vs metoprolol succinate on mortality in heart failure with reduced ejection fraction.
Ajam T, Ajam S, Devaraj S, Mohammed K, Sawada S, Kamalesh M. Ajam T, et al. Am Heart J. 2018 May;199:1-6. doi: 10.1016/j.ahj.2018.01.005. Epub 2018 Jan 31. Am Heart J. 2018. PMID: 29754646
METHODS: The VA's databases were queried to identify 114,745 patients diagnosed with HFrEF from 2007 to 2015 who were prescribed carvedilol and metoprolol succinate. ...RESULTS: A total of 43,941 metoprolol patients were matched with as many carvedilol patien …
METHODS: The VA's databases were queried to identify 114,745 patients diagnosed with HFrEF from 2007 to 2015 who were prescribed c
3,972 results